<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">34729561</PMID><DateRevised><Year>2024</Year><Month>09</Month><Day>23</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2692-8205</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2021</Year><Month>Jul</Month><Day>07</Day></PubDate></JournalIssue><Title>bioRxiv : the preprint server for biology</Title><ISOAbbreviation>bioRxiv</ISOAbbreviation></Journal><ArticleTitle>An Autoantigen Profile from Jurkat T-Lymphoblasts Provides a Molecular Guide for Investigating Autoimmune Sequelae of COVID-19.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">2021.07.05.451199</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1101/2021.07.05.451199</ELocationID><Abstract><AbstractText>In order to understand autoimmune phenomena contributing to the pathophysiology of COVID-19 and post-COVID syndrome, we have been profiling autoantigens (autoAgs) from various cell types. Although cells share numerous autoAgs, each cell type gives rise to unique COVID-altered autoAg candidates, which may explain the wide range of symptoms experienced by patients with autoimmune sequelae of SARS-CoV-2 infection. Based on the unifying property of affinity between autoantigens (autoAgs) and the glycosaminoglycan dermatan sulfate (DS), this paper reports 140 candidate autoAgs identified from proteome extracts of human Jurkat T-cells, of which at least 105 (75%) are known targets of autoantibodies. Comparison with currently available multi-omic COVID-19 data shows that 125 (89%) of DS-affinity proteins are altered at protein and/or RNA levels in SARS-CoV-2-infected cells or patients, with at least 94 being known autoAgs in a wide spectrum of autoimmune diseases and cancer. Protein alterations by ubiquitination and phosphorylation in the viral infection are major contributors of autoAgs. The autoAg protein network is significantly associated with cellular response to stress, apoptosis, RNA metabolism, mRNA processing and translation, protein folding and processing, chromosome organization, cell cycle, and muscle contraction. The autoAgs include clusters of histones, CCT/TriC chaperonin, DNA replication licensing factors, proteasome and ribosome proteins, heat shock proteins, serine/arginine-rich splicing factors, 14-3-3 proteins, and cytoskeletal proteins. AutoAgs such as LCP1 and NACA that are altered in the T cells of COVID patients may provide insight into T-cell responses in the viral infection and merit further study. The autoantigen-ome from this study contributes to a comprehensive molecular map for investigating acute, subacute, and chronic autoimmune disorders caused by SARS-CoV-2.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Julia Y</ForeName><Initials>JY</Initials><AffiliationInfo><Affiliation>Curandis, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Wei</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Gastroenterology, Affiliated Hospital of Guizhou Medical University, Guizhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Roehrl</LastName><ForeName>Michael W</ForeName><Initials>MW</Initials><AffiliationInfo><Affiliation>Curandis, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Roehrl</LastName><ForeName>Victor B</ForeName><Initials>VB</Initials><AffiliationInfo><Affiliation>Curandis, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Roehrl</LastName><ForeName>Michael H</ForeName><Initials>MH</Initials><AffiliationInfo><Affiliation>Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P30 CA008748</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21 CA251992</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D000076942">Preprint</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>07</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>bioRxiv</MedlineTA><NlmUniqueID>101680187</NlmUniqueID><ISSNLinking>2692-8205</ISSNLinking></MedlineJournalInfo><CommentsCorrectionsList><CommentsCorrections RefType="UpdateIn"><RefSource>This article has been published with doi: 10.1071/CH22268</RefSource></CommentsCorrections></CommentsCorrectionsList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Autoantigens</Keyword><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">SARS-Cov-2</Keyword><Keyword MajorTopicYN="N">autoantibodies</Keyword><Keyword MajorTopicYN="N">autoimmunity</Keyword><Keyword MajorTopicYN="N">long COVID</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>11</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>11</Month><Day>4</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>11</Month><Day>3</Day><Hour>7</Hour><Minute>2</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>11</Month><Day>2</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34729561</ArticleId><ArticleId IdType="pmc">PMC8562547</ArticleId><ArticleId IdType="doi">10.1101/2021.07.05.451199</ArticleId><ArticleId IdType="pii">2021.07.05.451199</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Wang J. Y., Zhang W., Roehrl M. W., Roehrl V. B., Roehrl M. H.. An Autoantigen Atlas from Human Lung HFL1 Cells Offers Clues to Neurological and Diverse Autoimmune Manifestations of COVID-19. bioRxiv, 2021:2021.01.24.427965.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8987778</ArticleId><ArticleId IdType="pubmed">35401574</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang J. Y., Zhang W., Roehrl M. W., Roehrl V. B., Roehrl M. H.. An Autoantigen Profile of Human A549 Lung Cells Reveals Viral and Host Etiologic Molecular Attributes of Autoimmunity in COVID-19. bioRxiv, 2021:2021.02.21.432171.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8075847</ArticleId><ArticleId IdType="pubmed">33971585</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang J. Y., Zhang W., Roehrl V. B., Roehrl M. W., Roehrl M. H.. An Autoantigen-ome from HS-Sultan B-Lymphoblasts Offers a Molecular Map for Investigating Autoimmune Sequelae of COVID-19. bioRxiv, 2021:2021.04.05.438500.</Citation></Reference><Reference><Citation>Wang J. Y., Zhang W., Roehrl M. W., Roehrl V. B., Roehrl M. H.. An autoantigen profile of human A549 lung cells reveals viral and host etiologic molecular attributes of autoimmunity in COVID-19. Journal of autoimmunity, 2021;120:102644.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8075847</ArticleId><ArticleId IdType="pubmed">33971585</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang J. Y., Lee J., Yan M., Rho J. H., Roehrl M. H.. Dermatan sulfate interacts with dead cells and regulates CD5(+) B-cell fate: implications for a key role in autoimmunity. Am J Pathol, 2011;178:2168&#x2013;76.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3081202</ArticleId><ArticleId IdType="pubmed">21514431</ArticleId></ArticleIdList></Reference><Reference><Citation>Rho J. H., Zhang W., Murali M., Roehrl M. H., Wang J. Y.. Human proteins with affinity for dermatan sulfate have the propensity to become autoantigens. Am J Pathol, 2011;178:2177&#x2013;90.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3081203</ArticleId><ArticleId IdType="pubmed">21514432</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee J., Rho J.-h., Roehrl M. H., Wang J. Y.. Dermatan Sulfate Is a Potential Master Regulator of IgH via Interactions with Pre-BCR, GTF2I, and BiP ER Complex in Pre-B Lymphoblasts. bioRxiv, 2021:2021.01.18.427153.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8185350</ArticleId><ArticleId IdType="pubmed">34113352</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee J., Rho J. H., Roehrl M. H., Wang J. Y.. Dermatan Sulfate Is a Potential Regulator of IgH via Interactions With Pre-BCR, GTF2I, and BiP ER Complex in Pre-B Lymphoblasts. Frontiers in immunology, 2021;12:680212.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8185350</ArticleId><ArticleId IdType="pubmed">34113352</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang J. Y., Zhang W., Rho J. H., Roehrl M. W., Roehrl M. H.. A proteomic repertoire of autoantigens identified from the classic autoantibody clinical test substrate HEp-2 cells. Clinical proteomics, 2020;17:35.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7507713</ArticleId><ArticleId IdType="pubmed">32973414</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang W., Rho J. H., Roehrl M. H., Wang J. Y.. A comprehensive autoantigen-ome of autoimmune liver diseases identified from dermatan sulfate affinity enrichment of liver tissue proteins. BMC immunology, 2019;20:21.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6595630</ArticleId><ArticleId IdType="pubmed">31242852</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang W., Rho J. H., Roehrl M. W., Roehrl M. H., Wang J. Y.. A repertoire of 124 potential autoantigens for autoimmune kidney diseases identified by dermatan sulfate affinity enrichment of kidney tissue proteins. PloS one, 2019;14:e0219018.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6592568</ArticleId><ArticleId IdType="pubmed">31237920</ArticleId></ArticleIdList></Reference><Reference><Citation>Consiglio C. R., Cotugno N., Sardh F., Pou C., Amodio D., Rodriguez L. et al. The Immunology of Multisystem Inflammatory Syndrome in Children with COVID-19. Cell, 2020;183:968&#x2013;81.e7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7474869</ArticleId><ArticleId IdType="pubmed">32966765</ArticleId></ArticleIdList></Reference><Reference><Citation>Gruber C. N., Patel R. S., Trachtman R., Lepow L., Amanat F., Krammer F. et al. Mapping Systemic Inflammation and Antibody Responses in Multisystem Inflammatory Syndrome in Children (MIS-C). Cell, 2020;183:982&#x2013;95.e14.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7489877</ArticleId><ArticleId IdType="pubmed">32991843</ArticleId></ArticleIdList></Reference><Reference><Citation>Gagiannis D., Steinestel J., Hackenbroch C., Schreiner B., Hannemann M., Bloch W. et al. Clinical, Serological, and Histopathological Similarities Between Severe COVID-19 and Acute Exacerbation of Connective Tissue Disease-Associated Interstitial Lung Disease (CTD-ILD). Frontiers in immunology, 2020;11:587517.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7566417</ArticleId><ArticleId IdType="pubmed">33123171</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou Y., Han T., Chen J., Hou C., Hua L., He S. et al. Clinical and Autoimmune Characteristics of Severe and Critical Cases of COVID-19. Clinical and translational science, 2020;13:1077&#x2013;86.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7264560</ArticleId><ArticleId IdType="pubmed">32315487</ArticleId></ArticleIdList></Reference><Reference><Citation>Fujii H., Tsuji T., Yuba T., Tanaka S., Suga Y., Matsuyama A. et al. High levels of anti-SSA/Ro antibodies in COVID-19 patients with severe respiratory failure: a case-based review : High levels of anti-SSA/Ro antibodies in COVID-19. Clinical rheumatology, 2020;39:3171&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7447083</ArticleId><ArticleId IdType="pubmed">32844364</ArticleId></ArticleIdList></Reference><Reference><Citation>Sacchi M. C., Tamiazzo S., Stobbione P., Agatea L., De Gaspari P., Stecca A. et al. SARS-CoV-2 Infection as a trigger of autoimmune response. Clinical and translational science, 2020.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8212749</ArticleId><ArticleId IdType="pubmed">33306235</ArticleId></ArticleIdList></Reference><Reference><Citation>Franke C., Ferse C., Kreye J., Reincke S. M., Sanchez-Sendin E., Rocco A. et al. High frequency of cerebrospinal fluid autoantibodies in COVID-19 patients with neurological symptoms. Brain, behavior, and immunity, 2020.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7834471</ArticleId><ArticleId IdType="pubmed">33359380</ArticleId></ArticleIdList></Reference><Reference><Citation>Zuo Y., Yalavarthi S., Navaz S., Hoy C., Shi H., Harbaugh A. et al. Autoantibodies stabilize neutrophil extracellular traps in COVID-19. medRxiv : the preprint server for health sciences, 2021.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8410057</ArticleId><ArticleId IdType="pubmed">34166229</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang S. E., Feng A., Meng W., Apostolidis S. A., Mack E., Artandi M. et al. New-Onset IgG Autoantibodies in Hospitalized Patients with COVID-19. medRxiv : the preprint server for health sciences, 2021.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8440763</ArticleId><ArticleId IdType="pubmed">34521836</ArticleId></ArticleIdList></Reference><Reference><Citation>Bastard P., Rosen L. B., Zhang Q., Michailidis E., Hoffmann H. H., Zhang Y. et al. Autoantibodies against type I IFNs in patients with life-threatening COVID-19. Science (New York, NY), 2020;370.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7857397</ArticleId><ArticleId IdType="pubmed">32972996</ArticleId></ArticleIdList></Reference><Reference><Citation>Guilmot A., Maldonado Slootjes S., Sellimi A., Bronchain M., Hanseeuw B., Belkhir L. et al. Immune-mediated neurological syndromes in SARS-CoV-2-infected patients. J Neurol, 2020:1&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7391231</ArticleId><ArticleId IdType="pubmed">32734353</ArticleId></ArticleIdList></Reference><Reference><Citation>Imai H., Chan E. K., Kiyosawa K., Fu X. D., Tan E. M.. Novel nuclear autoantigen with splicing factor motifs identified with antibody from hepatocellular carcinoma. The Journal of clinical investigation, 1993;92:2419&#x2013;26.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC288425</ArticleId><ArticleId IdType="pubmed">8227358</ArticleId></ArticleIdList></Reference><Reference><Citation>Beutgen V. M., Schmelter C., Pfeiffer N., Grus F. H.. Autoantigens in the trabecular meshwork and glaucoma-specific alterations in the natural autoantibody repertoire. Clinical &amp; translational immunology, 2020;9:e01101.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7049230</ArticleId><ArticleId IdType="pubmed">32140226</ArticleId></ArticleIdList></Reference><Reference><Citation>Becker A., Ludwig N., Keller A., Tackenberg B., Eienbroker C., Oertel W. H. et al. Myasthenia gravis: analysis of serum autoantibody reactivities to 1827 potential human autoantigens by protein macroarrays. PloS one, 2013;8:e58095.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3587426</ArticleId><ArticleId IdType="pubmed">23483977</ArticleId></ArticleIdList></Reference><Reference><Citation>Szklarczyk D., Gable A. L., Lyon D., Junge A., Wyder S., Huerta-Cepas J. et al. STRING v11: protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. Nucleic Acids Res, 2019;47:D607&#x2013;D13.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6323986</ArticleId><ArticleId IdType="pubmed">30476243</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou Y., Zhou B., Pache L., Chang M., Khodabakhshi A. H., Tanaseichuk O. et al. Metascape provides a biologist-oriented resource for the analysis of systems-level datasets. Nat Commun, 2019;10:1523.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6447622</ArticleId><ArticleId IdType="pubmed">30944313</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang J. Y., Wang X. M., Xing X., Xu Z., Zhang C., Song J. W. et al. Single-cell landscape of immunological responses in patients with COVID-19. Nature immunology, 2020;21:1107&#x2013;18.</Citation><ArticleIdList><ArticleId IdType="pubmed">32788748</ArticleId></ArticleIdList></Reference><Reference><Citation>Davies J. P., Almasy K. M., McDonald E. F., Plate L.. Comparative Multiplexed Interactomics of SARS-CoV-2 and Homologous Coronavirus Nonstructural Proteins Identifies Unique and Shared Host-Cell Dependencies. ACS infectious diseases, 2020;6:3174&#x2013;89.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7724760</ArticleId><ArticleId IdType="pubmed">33263384</ArticleId></ArticleIdList></Reference><Reference><Citation>Klann K., Bojkova D., Tascher G., Ciesek S., M&#xfc;nch C., Cinatl J.. Growth Factor Receptor Signaling Inhibition Prevents SARS-CoV-2 Replication. Molecular cell, 2020;80:164&#x2013;74.e4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7418786</ArticleId><ArticleId IdType="pubmed">32877642</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun J., Ye F., Wu A., Yang R., Pan M., Sheng J. et al. Comparative Transcriptome Analysis Reveals the Intensive Early Stage Responses of Host Cells to SARS-CoV-2 Infection. Frontiers in microbiology, 2020;11:593857.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7723856</ArticleId><ArticleId IdType="pubmed">33324374</ArticleId></ArticleIdList></Reference><Reference><Citation>Bojkova D., Klann K., Koch B., Widera M., Krause D., Ciesek S. et al. Proteomics of SARS-CoV-2-infected host cells reveals therapy targets. Nature, 2020;583:469&#x2013;72.</Citation><ArticleIdList><ArticleId IdType="pubmed">32408336</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilk A. J., Rustagi A., Zhao N. Q., Roque J., Mart&#xed;nez-Col&#xf3;n G. J., McKechnie J. L. et al. A single-cell atlas of the peripheral immune response in patients with severe COVID-19. Nature medicine, 2020;26:1070&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7382903</ArticleId><ArticleId IdType="pubmed">32514174</ArticleId></ArticleIdList></Reference><Reference><Citation>Lieberman N. A. P., Peddu V., Xie H., Shrestha L., Huang M. L., Mears M. C. et al. In vivo antiviral host transcriptional response to SARS-CoV-2 by viral load, sex, and age. PLoS biology, 2020;18:e3000849.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7478592</ArticleId><ArticleId IdType="pubmed">32898168</ArticleId></ArticleIdList></Reference><Reference><Citation>Riva L., Yuan S., Yin X., Martin-Sancho L., Matsunaga N., Pache L. et al. Discovery of SARS-CoV-2 antiviral drugs through large-scale compound repurposing. Nature, 2020;586:113&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7603405</ArticleId><ArticleId IdType="pubmed">32707573</ArticleId></ArticleIdList></Reference><Reference><Citation>Bouhaddou M., Memon D., Meyer B., White K. M., Rezelj V. V., Correa Marrero M. et al. The Global Phosphorylation Landscape of SARS-CoV-2 Infection. Cell, 2020;182:685&#x2013;712.e19.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7321036</ArticleId><ArticleId IdType="pubmed">32645325</ArticleId></ArticleIdList></Reference><Reference><Citation>Blanco-Melo D., Nilsson-Payant B. E., Liu W. C., Uhl S., Hoagland D., M&#xf8;ller R. et al. Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19. Cell, 2020;181:1036&#x2013;45.e9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7227586</ArticleId><ArticleId IdType="pubmed">32416070</ArticleId></ArticleIdList></Reference><Reference><Citation>Shen B., Yi X., Sun Y., Bi X., Du J., Zhang C. et al. Proteomic and Metabolomic Characterization of COVID-19 Patient Sera. Cell, 2020;182:59&#x2013;72.e15.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7254001</ArticleId><ArticleId IdType="pubmed">32492406</ArticleId></ArticleIdList></Reference><Reference><Citation>Lamers M. M., Beumer J., van der Vaart J., Knoops K., Puschhof J., Breugem T. I. et al. SARS-CoV-2 productively infects human gut enterocytes. Science (New York, NY), 2020;369:50&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7199907</ArticleId><ArticleId IdType="pubmed">32358202</ArticleId></ArticleIdList></Reference><Reference><Citation>Gordon D. E., Jang G. M., Bouhaddou M., Xu J., Obernier K., White K. M. et al. A SARS-CoV-2 protein interaction map reveals targets for drug repurposing. Nature, 2020;583:459&#x2013;68.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7431030</ArticleId><ArticleId IdType="pubmed">32353859</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiong Y., Liu Y., Cao L., Wang D., Guo M., Jiang A. et al. Transcriptomic characteristics of bronchoalveolar lavage fluid and peripheral blood mononuclear cells in COVID-19 patients. Emerging microbes &amp; infections, 2020;9:761&#x2013;70.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7170362</ArticleId><ArticleId IdType="pubmed">32228226</ArticleId></ArticleIdList></Reference><Reference><Citation>Vanderheiden A., Ralfs P., Chirkova T., Upadhyay A. A., Zimmerman M. G., Bedoya S. et al. Type I and Type III Interferons Restrict SARS-CoV-2 Infection of Human Airway Epithelial Cultures. Journal of virology, 2020;94.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7495371</ArticleId><ArticleId IdType="pubmed">32699094</ArticleId></ArticleIdList></Reference><Reference><Citation>Appelberg S., Gupta S., Svensson Akusj&#xe4;rvi S., Ambikan A. T., Mikaeloff F., Saccon E. et al. Dysregulation in Akt/mTOR/HIF-1 signaling identified by proteo-transcriptomics of SARS-CoV-2 infected cells. Emerging microbes &amp; infections, 2020;9:1748&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7473213</ArticleId><ArticleId IdType="pubmed">32691695</ArticleId></ArticleIdList></Reference><Reference><Citation>Stukalov A., Girault V., Grass V., Bergant V., Karayel O., Urban C. et al. Multi-level proteomics reveals host-perturbation strategies of SARS-CoV-2 and SARS-CoV. bioRxiv, 2020:2020.06.17.156455.</Citation><ArticleIdList><ArticleId IdType="pubmed">0</ArticleId></ArticleIdList></Reference><Reference><Citation>Emanuel W., Kirstin M., Vedran F., Asija D., Theresa G. L., Roberto A. et al. Bulk and single-cell gene expression profiling of SARS-CoV-2 infected human cell lines identifies molecular targets for therapeutic intervention. bioRxiv, 2020:2020.05.05.079194.</Citation></Reference><Reference><Citation>Liao M., Liu Y., Yuan J., Wen Y., Xu G., Zhao J. et al. Single-cell landscape of bronchoalveolar immune cells in patients with COVID-19. Nature medicine, 2020;26:842&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pubmed">32398875</ArticleId></ArticleIdList></Reference><Reference><Citation>Laurent E. M. N., Sofianatos Y., Komarova A., Gimeno J.-P., Tehrani P. S., Kim D.-K. et al. Global BioID-based SARS-CoV-2 proteins proximal interactome unveils novel ties between viral polypeptides and host factors involved in multiple COVID19-associated mechanisms. bioRxiv, 2020:2020.08.28.272955.</Citation></Reference><Reference><Citation>Li Y., Wang Y., Liu H., Sun W., Ding B., Zhao Y. et al. Urine proteome of COVID-19 patients. Urine (Amst), 2020;2:1&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7933783</ArticleId><ArticleId IdType="pubmed">33688631</ArticleId></ArticleIdList></Reference><Reference><Citation>Alexopoulos H., Magira E., Bitzogli K., Kafasi N., Vlachoyiannopoulos P., Tzioufas A. et al. Anti-SARS-CoV-2 antibodies in the CSF, blood-brain barrier dysfunction, and neurological outcome: Studies in 8 stuporous and comatose patients. Neurology(R) neuroimmunology &amp; neuroinflammation, 2020;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7577546</ArticleId><ArticleId IdType="pubmed">32978291</ArticleId></ArticleIdList></Reference><Reference><Citation>Wabnitz G., Balta E., Samstag Y.. L-plastin regulates the stability of the immune synapse of naive and effector T-cells. Advances in biological regulation, 2017;63:107&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pubmed">27720134</ArticleId></ArticleIdList></Reference><Reference><Citation>Mossabeb R., Seiberler S., Mittermann I., Reininger R., Spitzauer S., Natter S. et al. Characterization of a novel isoform of alpha-nascent polypeptide-associated complex as IgE-defined autoantigen. The Journal of investigative dermatology, 2002;119:820&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">12406326</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>